HD Medical at CES Unveils HealthyU™, the World’s First Intelligent All-in-one Remote Patient Monitor for Telehealth and Wellness
11.1.2021 16:05:00 EET | Business Wire | Press release
At CES’21, HD Medical Inc. today introduces HealthyU™, an intelligent remote patient monitoring device, in response to the ongoing challenges of remote Telehealth, Cardiac Care, and Wellness during the pandemic and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005444/en/
HealthyU™, the World’s First Intelligent All-in-one Remote Patient Monitor for Telehealth and Wellness. HD Medical Inc.'s HealthyU™ is an at-home monitoring device that addresses the ongoing challenges of remote Telehealth, Cardiac Care, and Wellness during the pandemic and beyond. (Graphic: Business Wire)
HealthyU™ is the first home device to provide:
- 7-lead ECG (without wires)
- Heart Sounds with Murmur Analysis
- Lung Sounds
- Heart Rate
- Pulse Oximetry (SpO2 / blood oxygen saturation)
- Temperature
- Respiratory Rate
- Cuffless Blood Pressure Trend
The Future of Telehealth, Home Monitoring, and Wellness
As the medical community seek new ways to deliver care, HealthyU™ takes multiple complex healthcare devices and turns them into one easy-to-use device for the patient and the provider to connect via a simple HD App and HD Cloud Platform for Intelligent Insights, or also with any video conferencing and screen sharing tool for Remote Consultation.
Providers can listen live to the heart and lung sounds using HD Steth™, HD Medical’s flagship intelligent stethoscope technology, cleared by FDA in July 2020 for Electronic Stethoscope, Phonocardiograph and Electrocardiograph.
Created with and available first to those with cardiac care and monitoring needs, HealthyU™ is available to clinical partners for research and corporate wellness partners seeking employee wellness offerings of this caliber, as well as for Telehealth pilot programs under IRB Protocol in accordance with FDA Regulations. HD Medical will be seeking Emergency Use Authorization from the FDA to make available in the U.S. and enable fully informed at-home doctor-patient visits during the pandemic and beyond.
HD Medical at CES Unveils HealthyU
“I’ve been treating patients remotely for nearly a year now and the pandemic has severely limited my ability to understand my patient’s condition. As we move forward, telehealth represents a paradigm shift in healthcare delivery during the pandemic and beyond. HealthyU will play a critical role and promises to not only save lives but also improve the quality of life for all patients,” said Dr. Nelson B. Schiller, MD, FACC, FRCP, Professor of Medicine & Anesthesia, UCSF.
"HealthyU is one of those rare medical devices that is truly a game changer in patient care. Being so user friendly and clinically sound, this device can be used in many different clinical scenarios and can truly be a lifesaver for multitudes of patients, who have the possibility of obtaining care while at home," said Dr. Shaun Setty, MD of The Larry and Helen Hoag Endowed Chair of Pediatric Cardiovascular Surgery in Los Angeles, CA.
“2020 has put greater emphasis on the need to advance remote patient monitoring technology, which is why we have prioritized bringing integrated sensors and intelligent insights into the home making it easy for patients to use and viable for providers to leverage during care,” said Arvind Thiagarajan, founder and CEO of HD Medical. “HealthyU™ performs wireless ECG outside of the hospital while incorporating auscultation and other important vitals. By simplifying the remote monitoring process, we’ve ensured this technology can be leveraged by anyone that needs it.”
HealthyU is currently intended for investigational use only, not for sale in the United States until after FDA clearance. HD Medical expects that HealthyU will be available for sale in the US by the third quarter of 2021, subject to FDA clearance process, which is being undertaken expeditiously. In the meantime, HealthyU will be available to clinical partners for research and corporate wellness programs, as well as telehealth pilot programs under the IRB protocol in accordance with FDA regulations.
To become a HealthyU™ partner, email info@hdmedicalgroup.com.
About HD Medical, Inc.
HD Medical, Inc. is a Silicon Valley-based innovator of digital health solutions for AI-enabled detection and management of cardiovascular disease (CVD). HD Steth has been awarded FDA clearance (K201299). The company delivers its intelligent cardiac care solutions and products globally to medical professionals and institutions through channel partners. Visit www.HealthyU.ai and www.hdmedicalgroup.com.
Note to editors: HealthyU, HD Steth, HD App, and HD Cloud Platform are registered trademarks of HD Medical, Inc. All other product, service or organization names remain the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005444/en/
Contact information
Kristi Furrer
HD Medical, Inc.
kristi@hdmedicalgroup.com
408-908-8900
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 14:00:00 EEST | Press release
Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performance, reliability and trusted supply chains. Its drones support national security and public-safety operations, sear
Enhertu ® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 14:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DESTI
SLB Announces Second-Quarter 2026 Results24.7.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8,721 $8,546 3% 5% Income before taxes - GAAP basis $1,018 $956 $1,285 6% -21% Income before taxes margin - GAAP basis 11.3% 11.0% 15.0% 38 bps -369 bps Net income attributable to SLB - GAAP basis $786 $752 $1,014 5% -22% Diluted EPS - GAAP basis $0.52 $0.50 $0.74 4% -30% Adjusted EBITDA* $1,899 $1,773 $2,051 7% -7% Adjusted EBITDA margin* 21.2% 20.3% 24.0% 83 bps -284 bps Pretax segment operating income* $1,404 $1,321 $1,584 6% -11% Pretax segment operating margin* 15.6% 15.2% 18.5% 49 bps -289 bps Net income attributable to SLB, excluding charges & credits* $833 $783 $1,0
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 13:30:00 EEST | Press release
NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps businesses realize the full value of NIQ's trusted market intelligence by automatically surfacing the trends, opportunities and
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 11:05:00 EEST | Press release
In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-government agreement, funded under the European Union’s SAFE programme, underlines the high level of partnership between France and Romania. The first delivery is expected in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260724603527/en/ The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200MM/A) radars to protect the Romanian airspace. The GM200 MM/A is a combat-proven medium-range 4D AESA radar, already deployed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom